Related Experiment Video
Updated: May 16, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Baseline-transmitted V106V/I/M non-nucleoside reverse transcriptase inhibitor resistance in HIV-1 subtype B infection
Elizabeth Sherman1, Shara Elrod, Paula Eckardt
1Nova Southeastern University, Fort Lauderdale, Florida, USA. esherman@nova.edu
Abstract:
We report a case in which an antiretroviral therapy (ART)-naïve patient diagnosed with HIV-1 subtype B presented with baseline genotype and phenotype resistance tests, confirming a V106V/I/M nucleoside resistance mutation. The V106V/I/M mutation represents a mixture of virus strains conferring resistance to the non-nucleoside reverse transcriptase inhibitor antiretrovirals efavirenz and nevirapine. V106M mutation is not often observed as a primary resistance mutation in patients infected with HIV-1 subtype B. The patient responded well to an ART regimen consisting of tenofovir-emtricitabine and raltegravir, achieving and maintaining an undetectable HIV RNA.
More Related Videos
Related Concept Videos
Retrovirus Life Cycles
Retroviruses
Viral Mutations
Size and Structure of Viral Genomes
Viruses with RNA Genomes
Inhibitors of Viral Protein Synthesis

